 AIM ImmunoTech Inc NYSE:AIM revealed that it has received a notification from the US Food and Drug Administration FDA stating that the clinical hold on the companys investigational new drug IND application for a Phase 2 study of its flagship drug candidate Ampligen as a therapy for locally advanced pancreatic cancer AMP-270 has been lifted. The Ocala, Florida-based immuno-pharma company said that it can now proceed with the study. 